Showing results (1501-1510 of 1,508) with videos related to
Sort By:
Pageof 151
You have reached the last page of results.This site can display upto 1,508 results.
NPJ Precision Oncology|July 3, 2026
Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II studyYeong Hak Bang, Dawon Kang, Seungwon Lee, et al.Science Translational Medicine|February 22, 2023
Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in <i>BRCA1 or BRCA2</i>Priya Bhardwaj, Neil M Iyengar, Heba Zahid, et al.Endocrinology and Metabolism (Seoul, Korea)|March 27, 2019
Medical Treatment with Somatostatin Analogues in Acromegaly: Position StatementSang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, et al.Endocrinology and Metabolism (Seoul, Korea)|July 2, 2025
2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid CarcinomaEun Kyung Lee, Min Joo Kim, Seung Heon Kang, et al.Endocrinology and Metabolism (Seoul, Korea)|July 4, 2020
Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric EndocrinologyJung Hee Kim, Hyun Wook Chae, Sang Ouk Chin, et al.Blood|October 8, 2025
Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell TransplantationBernard Ng, Andrew C Harris, Sayeh Abdossamadi, et al.Transplantation and Cellular Therapy|October 1, 2025
Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study CohortBernard Ng, Andrew C Harris, Sayeh Abdossamadi, et al.Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.Pageof 151